In 2000 the EU Commission introduced new regulations to incentivise investment in rare diseases. The results have been significant, before only 8 orphan-like medicines were available for patients while in just 18 years that number has risen to 164. But more needs to be done.
The bold idea
Without the Orphan Medicinal Products (OMP) regulation a positive future for millions of people living with rare disease will become even rarer. We won’t stop innovating to find new treatments.Yes
Think we can help?
We love working with brands that want to outsmart their competitors. If that sounds like you, let's talk.